Skip to main content

Advertisement

SpringerLink
Log in

Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose

IL28B genotypes have a strong impact on treatment outcomes of chronic hepatitis C (CHC) and on-treatment viral kinetics. Since metabolic regulation and interferon response are highly integrated, metabolic profiles may play an important role in the link between IL28B genotypes and hepatitis C virus (HCV) infection. Thus, the association of IL28B rs8099917 genotypes with metabolic profiles and the impact of metabolic profiles on hepatitis C viral kinetic parameters were examined.

Methods

A case–control analysis including 278 CHC patients and 280 subjects without chronic HCV infection was performed. The associations of IL28B rs8099917 genotype with pretreatment metabolic profiles and early viral kinetic parameters were evaluated.

Results

Compared to HCV genotype 1 patients, the differences in metabolic profiles were more significant in genotype 2 patients. HCV genotype 2 patients with TT genotype had higher serum total cholesterol and high density lipoprotein (HDL) levels than those with GT genotype, and the differences remained significant when adjusted for age, sex, and body mass index (p = 0.005 for total cholesterol; p = 0.006 for HDL). In addition, patients with higher serum TG, higher fasting blood glucose, and lower HDL had a lower viral clearance rate.

Conclusions

IL28B genotypes may affect lipid profiles of CHC patients, especially in HCV-genotype 2 patients. Patients with higher serum fasting blood glucose, triglyceride, and lower HDL have a lower viral clearance rate during pegylated interferon plus ribavirin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

HCV:

Hepatitis C virus

CHC:

Chronic hepatitis C

Peg-IFN:

Pegylated interferon

ALT:

Alanine aminotransferase

GGT:

Gamma-glutamyl transpeptidase

WBC:

White blood count

PLT:

Platelet count

BMI:

Body mass index

ULN:

Upper limit of normal

RVR:

Rapid virologic response

EVR:

Early virologic response

SVR:

Sustained virologic response

SNP:

Single nucleotide polymorphism

TG:

Triglyceride

TC:

Total cholesterol

HDL:

High density lipoprotein

LDL:

Low density lipoprotein

IR:

Insulin resistance

References

  1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2005;15(Suppl):E91–E96

    Article  Google Scholar 

  2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 1995;25:27–32

    PubMed  CAS  Google Scholar 

  3. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–1171

    Article  PubMed  Google Scholar 

  4. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–S244

    Article  PubMed  Google Scholar 

  5. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009;14:45–54

    PubMed  CAS  Google Scholar 

  6. Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009;104:598–604

    Article  PubMed  CAS  Google Scholar 

  7. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010;52:854–863

    Article  PubMed  CAS  Google Scholar 

  8. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10–12, 2002. Hepatology 2002;36:S3–S20

    Google Scholar 

  9. Fried MW, Hadziyannis SJ, Shiffman M, et al. Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008;48(Suppl 2):5A

    Article  Google Scholar 

  10. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801

    Article  PubMed  CAS  Google Scholar 

  11. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401

    Article  PubMed  CAS  Google Scholar 

  12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–1104

    Article  PubMed  CAS  Google Scholar 

  13. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109

    Article  PubMed  CAS  Google Scholar 

  14. O’Brien TR. Interferon-alpha, interferon-lambda and hepatitis C. Nat Genet 2009;41:1048–1050

    Article  PubMed  Google Scholar 

  15. Hsu CS, Hsu SJ, Chen HC, et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 2011;108:3719–3724

    Article  PubMed  CAS  Google Scholar 

  16. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021–1031

    Article  PubMed  CAS  Google Scholar 

  17. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52:1888–1896

    Article  PubMed  CAS  Google Scholar 

  18. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499–509

    Article  PubMed  CAS  Google Scholar 

  19. Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011;16:629–637

    Article  PubMed  CAS  Google Scholar 

  20. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645

    Article  PubMed  CAS  Google Scholar 

  21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl 1):S43–S48

    Google Scholar 

  22. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983

    Article  PubMed  CAS  Google Scholar 

  23. Prati D, Shiffman ML, Diago M, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 2006;44:679–685

    Article  PubMed  CAS  Google Scholar 

  24. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–1062

    Article  PubMed  Google Scholar 

  25. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63

    Article  PubMed  CAS  Google Scholar 

  26. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271–277

    Article  PubMed  CAS  Google Scholar 

  27. Hsu CS, Liu CJ, Lai MY, et al. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007;50:310–315

    Article  PubMed  CAS  Google Scholar 

  28. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659–666

    Article  PubMed  CAS  Google Scholar 

  29. Kao JH, Lin HH, Chen PJ, et al. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996;31:224–227

    Article  PubMed  CAS  Google Scholar 

  30. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201–207

    PubMed  CAS  Google Scholar 

  31. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103–107

    Article  PubMed  CAS  Google Scholar 

  32. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703–714

    Article  PubMed  CAS  Google Scholar 

  33. Hsu CS, Liu CJ, Liu CH, et al. Metabolic profiles in patients with chronic hepatitis C: a case–control study. Hepatol Int 2008;2:250–257

    Article  PubMed  Google Scholar 

  34. Harrison SA Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006;43:1168 (author reply 1168–1169)

    Google Scholar 

  35. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860–867

    Article  PubMed  CAS  Google Scholar 

  36. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570–576

    Article  PubMed  Google Scholar 

  37. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010;52:864–874

    Article  PubMed  CAS  Google Scholar 

  38. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145–150

    Article  PubMed  CAS  Google Scholar 

  39. Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089–1097

    Article  PubMed  CAS  Google Scholar 

  40. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102:2561–2566

    Article  PubMed  CAS  Google Scholar 

  41. Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007;14:600–607

    Article  PubMed  CAS  Google Scholar 

  42. Li JH, Lao XQ, Tillmann HL, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904–1911

    Article  PubMed  Google Scholar 

  43. Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011;55:1195–1200

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank colleagues in the National Taiwan University Hospital and its Yun-Lin Branch, who helped enroll and follow-up the patients, and research assistants who assisted in laboratory analyses and collected clinical information. They also thank Dr Ming-Yieh Peng, Hsiang-Lin Wan, and colleagues in the Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan, for enrolling and following up the study subjects. This work was supported in part by grants from the National Taiwan University Hospital, the Buddhist Tzu Chi General Hospital, Taipei Branch, the Department of Health, and the National Science Council, Executive Yuan, Taiwan TCRD-TPE-100-C1-2, NSC99-2314-B-303-004].

Conflict of interest

Pei-Jer Chen is a Consultant for Novartis, Roche, and Gilead Sciences. Ding-Shinn Chen is a Consultant for Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Roche, and Merck Sharp and Dohme. Jia-Horng Kao is a Consultant for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche; on speaker’s bureau for Abbott, Roche, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. All other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei, Taiwan

    Ching-Sheng Hsu

  2. School of Medicine, Tzu Chi University, Hualien, Taiwan

    Ching-Sheng Hsu

  3. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Shih-Jer Hsu, Chen-Hua Liu, Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen & Jia-Horng Kao

  4. Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan

    Shih-Jer Hsu

  5. Division of Personalized Nutrition and Medicine, National Center for Toxicological Research, FDA, Jefferson, USA

    Hung-Chia Chen

  6. Department of Internal Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Chen-Hua Liu, Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen & Jia-Horng Kao

  7. Center of Mathematical Modeling and Scientific Computing, National Chiao Tung University, Hsinchu, Taiwan

    Jenher Jeng

  8. Department of Medical Research, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Jia-Horng Kao

  9. Hepatitis Research Center, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Pei-Jer Chen & Jia-Horng Kao

Authors
  1. Ching-Sheng Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shih-Jer Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hung-Chia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen-Hua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jenher Jeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chun-Jen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pei-Jer Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ding-Shinn Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jia-Horng Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia-Horng Kao.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 69 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hsu, CS., Hsu, SJ., Chen, HC. et al. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int 7, 171–179 (2013). https://doi.org/10.1007/s12072-012-9390-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9390-3

Keywords

Search

Navigation